Table 1 Patient characteristics

From: Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias

Characteristic

Diagnosis

 

MDS

ALL

AML

CMML

Number of patients

446

385

1314

58

Age

64 (19–87)

41 (13–92)

59 (10–87)

65 (28–80)

PB blast (%)

1 (0–28)

32 (0–100)

23 (0–99)

1 (0–9)

BM blast (%)

14 (0–29)

86 (0–100)

48 (0–98)

7 (0–24)

Platelet count ( × 109/l)

41 (2–597)

50 (4–485)

48 (1–2292)

52 (7–492)

Lymphocyte count ( × 106/l)

1296 (54–34 486)

1837 (0–54 575)

1708 (0–39 060)

2040 (391–15 768)

LDH, U/l

652 (212–13 688)

1294 (268–42 001)

1035 (25–39 243)

811 (290–3212)

B2M, mg/l

2.8 (0.8–15.8)

3.0 (0–50.5)

2.8 (0–31.3)

4.1 (1.22–15)

Cytogenetics a

 Favorable

11 (3%)

16 (4%)

175 (31%)

0

 Intermediate

244 (55%)

271 (76%)

803 (62%)

49 (85%)

 Unfavorable

188 (42%)

71 (20%)

324 (25%)

9 (15%)

Response to therapy

 CR

227 (51%)

332 (90%)

745 (58%)

24 (41%)

 Other

215 (49%)

38 (10%)

547 (42%)

34 (59%)

Performance status

 0–2

422 (95%)

358 (95%)

1165 (90%)

52 (90%)

 3, 4

23 (5%)

17 (5%)

132 (10%)

6 (10%)

AHD

 Absent

144 (33%)

344 (93%)

816 (63%)

11 (19%)

 Present

297 (67%)

25 (7%)

481 (37%)

46 (81%)

  1. Data are presented as median (range) unless otherwise indicated.
  2. CR, complete response; AHD, antecedent hematologic disease.
  3. aIn AML and MDS, cytogenetic status was categorized as favorable (t(8;21), t(15;17), inv16)); unfavorable (−5/−7, 11q); or intermediate (others). For patients with ALL, cytogenetic status was categorized as favorable (hyperdiploidy), unfavorable (Philadelphia chromosome-positive), or intermediate (others).
Back to article page